The U.K. just cleared a drug to prevent breast cancer. U.S. women may not know it’s already an option
The news that the U.K. has approved a preventive drug for post-menopausal women at risk…
Category: cancer
The first vaccine for the increasingly prevalent chikungunya virus is here
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion
What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for…
Eli Lilly tries a rare tactic: competing on price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
HPV vaccines are so effective that new screening policies may be in order, suggests study
Vaccines work well to prevent cancers caused by the human papillomavirus (HPV). So well, in…
Why do some CAR-T cancer patients have severe complications? Data points to latent virus
The therapy, an infusion of CAR-T cells designed to kill the lymphoma, was going well….
Why preventative care is such a tough sell in the U.S., according to chronic disease experts
WASHINGTON – With the prevalence of some chronic diseases trending up, the U.S. needs to…
BioMarin’s new CEO inherits a profitable company, a pioneering gene therapy, and a brewing activist challenge
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In the fight against cancer, it’s boom times for radiopharmaceuticals
When Ken Song was getting ready to leave his job as the CEO of a…
Opinion: Many Americans receive too much health care. That may finally be changing
The opioid crisis rocked America, bringing addiction and overdose into the spotlight. But it also…
STAT+: FDA cites cancer links in seeking to withdraw approval of antibiotic used in pigs
After years of trying, the U.S. Food and Drug Administration is again seeking to withdraw…
.jpg)
STAT+: Drug shortages and the supply chain are a matter of national security, experts say
WASHINGTON – The pandemic showed how fragile the supply chain can be, and to fix…
STAT+: New insights into how tumor cells hijack brain plasticity to drive cancer
The idea that cancer can hijack brain plasticity — subverting supple connections in the healthy…
American Cancer Society expands lung cancer screening guidelines for cigarette smokers
Most lung cancer screening guidelines hinge on how much people smoked tobacco and when they…
Your Monday morning biotech news roundup
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Liquid biopsy for cancer recurrence creates a new kind of patient-in-waiting
My husband’s cancer came back this summer after not being evident for almost two years….
STAT+: ARPA-H head Renee Wegrzyn on the agency’s new Cambridge hub and plans for cancer research
CAMBRIDGE, MASS. — In an area long known as an epicenter of innovation and investment…
Opinion: The pink ribbon of breast cancer awareness needs a splash of blue for men
Everyone knows the universal symbol of breast cancer: the pink ribbon. Promoted by the Union…
Give Thanks for Foods from the Americas!
Foods like sweet potatoes, corn, and pumpkin are regulars on our Thanksgiving tables. Let’s take…
STAT+: Oncologists more likely to provide low-value care after receiving pharma money, study finds
Oncologists were more likely to provide low-value cancer care after receiving money from pharmaceutical companies,…
The XBI biotech index hit its lowest point since 2018. No one knows what comes next.
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: With an old approach but new energy, ADCs take center stage as promising cancer treatments
MADRID — If you had to pinpoint one subject that stood out at this year’s…
STAT+: Results on Novartis prostate cancer therapy could expand its use
MADRID — Results presented Monday could expand the use of a Novartis therapy for metastatic…
STAT+: Data on AstraZeneca cancer drug allay safety concerns but treatment still faces questions
MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs…
STAT+: In lung cancer, J&J data amount to latest salvo against AstraZeneca
MADRID — A competition has been brewing between two pharma titans — Johnson & Johnson…
STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients
MADRID — A Roche drug lowered the risk of recurrence or death by 76% versus…
STAT+: Study on Amgen’s ‘bispecific’ immunotherapy could lead to approval in small cell lung cancer
MADRID — A novel type of immunotherapy from Amgen generated strong response rates in patients…
STAT+: Pharmacists can make shortage drugs, but at what cost?
Pharmacists increasingly are being asked to make drugs in bulk for hospitals that are in…
.jpg)
STAT+: Merck, Daiichi Sankyo to partner on targeted chemotherapy drugs in deal worth up to $22 billion
MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a…
STAT+: What to watch at ESMO: readouts from trials in lung, prostate, and other types of cancer
Europe’s major cancer research conference kicks off in Madrid on Friday, with headline — and…
STAT+: Dana-Farber executive says split from Mass General will benefit patients
Laurie Glimcher trained at Massachusetts General Hospital. Her father was the chair of orthopedic surgery…
How rising stars in science and medicine think about mentorship and bouncing back from rejection
At the age of 26, Lauren Ghazal was diagnosed with Hodgkin’s lymphoma just months into…
Breast cancer is deadlier for Black women. A study of mammograms could help close the gap
Are 3D mammograms better than standard 2D imaging for catching advanced cancers? A clinical trial is recruiting…
STAT+: Dana-Farber’s divorce from Brigham is the culmination of decades of change
On the Southeast Expressway, at the edge of the city, two billboards advertising cancer care…
STAT+: Amgen reports first clinical data on new targeted cancer therapy
It’s been a busy week for a cancer drug target called PRMT5 that may play…
STAT+: Like a vampire, some cancer cells can suck the energy source from immune cells
As elite hunters of the immune system, T cells are constantly prowling our bodies for…
STAT+: EU orders Illumina to divest cancer diagnostics firm Grail
LONDON — European regulators on Thursday detailed their demands that Illumina divest the cancer diagnostics…
STAT+: Dana-Farber CEO on Mass General split: Boston needed a dedicated cancer hospital
One of the first items on Laurie Glimcher’s agenda after becoming CEO of the renowned…
STAT+: Sana to lay off nearly a third of staff, de-prioritize a key program
Sana Biotechnology, a startup that just a couple years ago raised over $1 billion off…
STAT+: Bristol ‘take-under’ of Mirati is not so great for biotech, but company’s new cancer target has potential
Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics: A take-under deal feels meh…
STAT+: Delfi launches its blood test to screen for lung cancer – and reveals challenges for liquid biopsies
Delfi Diagnostics, a well-funded startup in the burgeoning field of creating blood tests to detect…
STAT+: A Q&A with the global head of Boehringer Ingelheim’s innovation unit
LONDON — At an event here last week, the German pharmaceutical firm Boehringer Ingelheim outlined…
STAT+: Bristol Myers to buy cancer player Mirati for more than $4.8 billion
Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug…
STAT+: Long underappreciated, gamma-delta T cells may be key to colon cancer defense, study says
Within the linings of our guts, immune cells patrol like sentries on a castle wall….
STAT+: FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug
The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following…
The future of health care in the House
You’re reading the web edition of D.C. Diagnosis. Sign up here to receive this newsletter in your…
Cancer drug shortage eases slightly, but it’s still ‘living from paycheck to paycheck’
The shortage of cancer drugs is not going away, but it may be easing slightly,…
STAT+: 3 questions for the future of Biden’s cancer moonshot
WASHINGTON — The latest phase of President Biden’s Cancer Moonshot initiative leaves open a few…
STAT+: Was Amgen less than forthcoming about FDA’s concerns on its cancer drug?
Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug…
STAT+: Key Senate panel eyes action on drug shortages
WASHINGTON — One of the top health care committees in the Senate is assembling ideas…